-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Viroksavir in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Viroksavir in Seasonal Influenza Drug Details: Viroksavir is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Viroksavir in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Pandemic Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Viroksavir in Pandemic Influenza Drug Details: Viroksavir is under development for...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Viroksavir in Haemophilus influenzae Type A Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Haemophilus influenzae Type A Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Viroksavir in Haemophilus influenzae Type A Infections Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Viroksavir in Haemophilus influenzae Type B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Haemophilus influenzae Type B Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Viroksavir in Haemophilus influenzae Type B Infections Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anumigilimab in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Hidradenitis Suppurativa Drug Details: Anumigilimab (CSL324) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Acute Respiratory Distress Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anumigilimab in Acute Respiratory Distress Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Acute Respiratory Distress Syndrome Drug Details: Anumigilimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Silmitasertib in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Reparixin in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Community Acquired Pneumonia Drug Details: Reparixin (Repertaxin) is...